Biotron Limited (ASX: BIT) - Share Price

- Current share price for BIT : $0.002

Biotron Limited (BIT) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical stage publicly listed Australian Biotechnology Company based in Sydney, Australia. The company is developing and commercialising a novel small molecule approach that has the potential to treat a number of serious viral diseases. The technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus (RSV).

BIT General Information ⁺

ASX Code	BIT
Website	http://www.biotron.com.au
Industry/Sector	Biotechnology
Market Cap ($M)	5
BIT Share Price	$0.002
Day High	$0.002
Day Low	$0.002
Last Close	$0.002
BIT Share Price Movement	- ( No change )

Prices as at 16:40, 3 Nov 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Biotron Limited (BIT) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Biotron Limited (BIT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Biotron Limited (BIT) price-sensitive announcements

BIT - Quarterly Activities/Appendix 4C Cash Flow Report

Biotron Limited’s quarterly activities report and Appendix 4C for the quarter ended 30 Sep

Biotron Limited (BIT)
28 Oct 2026 | 10:32 AM

BIT - Appointment of CEO and Executive Director

Biotron Limited announced the appointment of Glenn Gilbert as Chief Executive Officer and

Biotron Limited (BIT)
14 Oct 2026 | 9:50 AM

BIT - Resignation of Managing Director and Appendix 3Z

Biotron Limited announced that Dr Michelle Miller resigned as Managing Director and Chief

Biotron Limited (BIT)
14 Sep 2026 | 10:36 AM

BIT - Full Year Statutory Accounts and Appendix 4E

Biotron Limited’s Appendix 4E Preliminary Final Report and audited statutory accounts for

Biotron Limited (BIT)
27 Aug 2026 | 1:21 PM

Biotron Limited (BIT) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Biotron Limited (BIT) ORDINARY FULLY PAID	Health Care	$6	Quarterly Activities/Appendix 4C Cash Flow Report	28 Oct 2026 10:32AM	$0.002	$0.002	fallen by 0%
Biotron Limited (BIT) ORDINARY FULLY PAID	Health Care	$6	Biotron Receives Additional $208,463 Tax Refund	23 Oct 2026 1:12PM	$0.002	$0.002	fallen by 0%
Biotron Limited (BIT) ORDINARY FULLY PAID	Health Care	$6	Annual Report/Notice of AGM/Proxy Form	23 Oct 2026 9:19AM	$0.002	$0.002	fallen by 0%
Biotron Limited (BIT) ORDINARY FULLY PAID	Health Care	$6	Director Appointment Michael Thurn & Appendix 3X	19 Oct 2026 8:43AM	$0.002	$0.002	fallen by 0%
Biotron Limited (BIT) ORDINARY FULLY PAID	Health Care	$6	Appointment of CEO and Executive Director	14 Oct 2026 9:50AM	$0.002	$0.002	fallen by 0%
Biotron Limited (BIT) ORDINARY FULLY PAID	Health Care	$6	Resignation of Managing Director and Appendix 3Z	14 Sep 2026 10:36AM	$0.002	$0.002	fallen by 0%

BIT Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$1.52	-$0.10	133.30%	0.00%	0.0%
2025A	-$0.32	N2	-90.90%	0.00%	0.0%
2024A	-$3.44	-$0.30	-10.80%	0.00%	0.0%

BIT Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Biotron Limited (BIT)	$6M	1.3333	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
CSL Limited (CSL)	$96,534M	0.7309	-0.4395	0.0602	12.4623	22.2350	20.9730	2.11%	2.12%	2.19%
Mesoblast Limited (MSB)	$2,811M	-0.4501	0.0000	0.0000	0.0000	0.0000	981.8182	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$1,871M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,452M	-1.3893	0.0000	-0.5230	0.0000	154.0636	322.9630	0.00%	0.00%	0.00%

BIT Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	1.82	0.00
Market	0.30	13.10	1.02	0.74
Sector	0.76	34.60	2.26	2.03

BIT Directors

Name	Position	Start Date
Dr Michael Joseph Thurn	Non-Executive Director	19 Oct 2026
Mr Michael James Medway	Non-Executive Director	16 Jul 2025
Mr Graeme Wald	Non-Executive Director	30 Mar 2026
Dr Paul Alexander Kasian	Non-Executive Director, Non-Executive Chairman	23 Dec 2025

Biotron Limited (BIT) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
13 Jul 2026	WALD, Graeme	Buy	Indirect Shares	16,276,333	$0.003	$48,828.999
13 Jul 2026	KASIAN, Paul	Buy	Indirect Shares	12,189,000	$0.003	$36,567.000
19 Dec 2025	MILLER, Michelle	Issued	Indirect Shares	1,200,000	$0.003	$3,600.000

See all changes in directors' interest & trades for Biotron Limited (BIT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

BIT Management

Name	Position
Marcelo Mora	Company Secretary

BIT Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Biotron Limited (BIT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
263,850,833 (9.50%)	10 Bolivianos Pty Ltd

BIT Calendar of Events

Date	Event
22 October 2027	Report (Annual)
26 August 2027	Report (Annual)
26 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us